Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
Ownership |
2021-03-25 2:14 pm |
N/A 2026-10-27 |
Chemomab Therapeutics Ltd. | CMMB | Darvish Nissim Director |
0 | $0 | 10,123 (Direct) |
View |
Ownership |
2021-03-25 10:12 am |
N/A N/A |
Chemomab Therapeutics Ltd. | CMMB | SQUINTO STEPHEN P Director |
0 | $0 | 144,856 (Direct) |
View |
Ownership |
2021-03-25 10:11 am |
N/A 2027-12-03 |
Chemomab Therapeutics Ltd. | CMMB | Aharon Arnon Chief Medical Officer |
0 | $0 | 75,232 (Direct) |
View |
Ownership |
2021-03-25 10:10 am |
N/A N/A |
Chemomab Therapeutics Ltd. | CMMB | Mor George Adi Chief Executive Officer 10% Owner |
0 | $0 | 1,329,468 (Direct) |
View |
| 2021-03-16 Option Award |
2021-03-18 9:59 pm |
N/A 2026-03-16 |
Chemomab Therapeutics Ltd. | CMMB | OrbiMed Israel GP Ltd. OrbiMed Israel BioFund GP Limited Partnership 10% Owner |
28,817 | $0 | 2,606,991 (Indirect) |
View |
| 2021-03-16 Option Award |
2021-03-18 9:59 pm |
N/A N/A |
Chemomab Therapeutics Ltd. | CMMB | OrbiMed Israel GP Ltd. OrbiMed Israel BioFund GP Limited Partnership 10% Owner |
288,170 | $17.35 | 2,606,991 (Indirect) |
View |
Ownership |
2021-03-18 9:41 pm |
N/A N/A |
Chemomab Therapeutics Ltd. | CMMB | THIEL PETER 10% Owner |
0 | $0 | 877,973 (Indirect) |
View |
| 2020-07-16 Option Award |
2021-03-12 4:28 pm |
N/A 2030-07-15 |
Anchiano Therapeutics Ltd. | ANCN | Polovets Stanislav Director |
55,000 | $0 | 55,000 (Direct) |
View |
| 2020-07-16 Option Award |
2021-03-11 6:33 pm |
N/A 2030-07-15 |
Anchiano Therapeutics Ltd. | ANCN | Cohen Neil Harris interim CEO |
55,000 | $0 | 55,000 (Direct) |
View |